Demographic characteristics, including age and sex, were collected and data concerning a history of atrial fibrillation (AF), diabetes mellitus, hypertension, coronary heart disease (CHD), current cigarette smoking, and current drinking status were obtained to assess stroke risk.
Laboratory tests were performed within 24 h of hospital admission under fasting conditions. Laboratory findings, including a red blood cell (RBC) count, white blood cell (WBC) count, platelet (PLT) count, and hemoglobin (Hb), fasting blood glucose, total bilirubin (TBIL), direct bilirubin (DB), indirect bilirubin (IDB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), and γ-glutamyltranspeptidase (γ-GT) levels were obtained for all patients. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria were used to classify the ischemic stroke subtypes [16 (link)]. Furthermore, the administration of anticoagulant and antiplatelet therapies for acute stroke during hospitalization before HT was recorded. Stroke severity was assessed within 24 h of admission by qualified neurologists using the National Institutes of Health Stroke Scale (NIHSS) score. In addition, the modified Rankin Scale (mRS) score was used to assess the neurological function of each patient at admission.
In the analysis, the TBIL level was taken as the main index representing bilirubin. All patients were divided into quartiles according to the distribution of their baseline serum TBIL level to examine whether any enhancement of performance could be quantified while maintaining sufficient statistical power in each category.
Free full text: Click here